Mechanism of Action
Dual Incretin Receptor Activation
Tirzepatide is a synthetic 39-amino acid peptide based on the native GIP sequence with structural modifications enabling GLP-1 receptor co-agonism. It acts as a balanced agonist at GIP receptors (primary) and GLP-1 receptors (secondary). The GIP component enhances insulin secretion, potentiates the GLP-1 effect on beta cells, and may uniquely reduce GLP-1-associated nausea through central GIP receptor activity, improving tolerability.
Adipose Tissue Effects
GIP receptors are highly expressed in adipose tissue. Tirzepatide's GIP agonism promotes lipid utilization, reduces adipocyte hypertrophy, and improves adiponectin secretion. Combined with GLP-1-mediated satiety, the dual mechanism produces additive effects on body weight that exceed what GLP-1 agonism alone can achieve.
Metabolic Pleiotropic Effects
Beyond glycemia and weight, tirzepatide improves insulin sensitivity in muscle and liver, reduces hepatic fat (NASH implications), lowers triglycerides, raises HDL cholesterol, and reduces blood pressure. SURPASS-CVOT cardiovascular outcomes data showed favorable trends.
Research Summary
Weight Loss (SURMOUNT Trials)
Strong EvidenceSURMOUNT-1 (non-diabetic, n=2539): 5, 10, 15 mg doses produced 15%, 19.5%, 20.9% mean weight reductions vs 3.1% placebo at 72 weeks. 96% of completers on 15 mg achieved >5% weight loss. SURMOUNT-2 (T2D): 13.9% and 15.7% weight reduction at 10 and 15 mg. SURMOUNT-3 (intensive lifestyle run-in): 26.6% weight loss with 15 mg. Results consistently surpass semaglutide 2.4 mg benchmarks.
Glycemic Control (SURPASS Trials)
Strong EvidenceSURPASS program across 7 trials demonstrated HbA1c reductions of 1.87-2.59% across doses, outperforming semaglutide 1 mg (SURPASS-2), insulin degludec (SURPASS-3), and insulin glargine (SURPASS-4). Time in range improvements and fasting glucose reductions were also superior across comparators.
Cardiovascular and Renal Outcomes
Active ResearchSURPASS-CVOT showed non-inferiority for MACE vs dulaglutide. SURMOUNT-MMO (cardiovascular outcomes in obesity) is ongoing. SURPASS-NEPHRO demonstrated meaningful reductions in urine albumin-creatinine ratio, suggesting renoprotective potential beyond glycemic control.
Calculate your Tirzepatide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Clinical Trial Data
| Phase | Trial | N | Duration | Key Outcome |
|---|---|---|---|---|
| Phase 3 | SURMOUNT-1 (obesity, no T2D) PMID:36535397 | 2,539 | 72 weeks | 20.9% mean body weight loss at 15 mg vs 3.1% placebo; 96% achieved >5% weight loss at 15 mg |
| Phase 3 | SURMOUNT-2 (obesity with T2D) PMID:37164658 | 938 | 72 weeks | 15.7% weight loss at 15 mg; HbA1c reduction 2.01%; superior to semaglutide 1 mg on both endpoints |
| Phase 3 | SURMOUNT-3 (lifestyle run-in) PMID:37946543 | 579 | 72 weeks | 26.6% total weight loss including intensive lifestyle lead-in; highest clinical weight loss trial outcome |
| Phase 3 | SURPASS-2 vs Semaglutide PMID:34170647 | 1,879 | 40 weeks | HbA1c -2.37% (tirzepatide 15mg) vs -1.86% (sema 1mg); 5.5 kg greater weight loss vs semaglutide |
| Phase 3 | SURPASS-CVOT PMID:36884381 | 12,712 | Ongoing | Non-inferiority to dulaglutide for MACE in T2D with high CV risk established; superiority analysis ongoing |
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Weight management | 2.5 mg/week x4 weeks, increase by 2.5 mg every 4 weeks to 10-15 mg maintenance | Weekly | Subcutaneous |
| Type 2 diabetes | 2.5 mg/week titrating to 5-15 mg/week based on response | Weekly | Subcutaneous |
Administer same day each week regardless of meals. Inject abdomen, thigh, or upper arm. Rotate sites.
Interactions
Safety Profile
GI side effects (nausea, diarrhea, vomiting) are the most common adverse events, occurring in 12-18% of participants at therapeutic doses, generally mild-to-moderate and transient. Injection site reactions are infrequent. Serious risks mirror GLP-1 class: pancreatitis, gallbladder disease, thyroid C-cell tumors (rodent data; contraindicated in MEN2/personal history of MTC), hypoglycemia (primarily with secretagogues). Muscle mass loss during rapid weight reduction is a practical concern addressed by combining with resistance training.
References
- [1]Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
- [2]Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515.
- [3]Wadden TA, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity. N Engl J Med. 2023;389(21):1961-1972.